TY - JOUR
T1 - Association between pathological and MRI findings in multiple sclerosis
AU - Filippi, Massimo
AU - Rocca, Maria A.
AU - Barkhof, Frederik
AU - Brück, Wolfgang
AU - Chen, Jacqueline T.
AU - Comi, Giancarlo
AU - DeLuca, Gabriele
AU - De Stefano, Nicola
AU - Erickson, Bradley J.
AU - Evangelou, Nikos
AU - Fazekas, Franz
AU - Geurts, Jeroen J.G.
AU - Lucchinetti, Claudia
AU - Miller, David H.
AU - Pelletier, Daniel
AU - Popescu, Bogdan F.Gh
AU - Lassmann, Hans
N1 - Funding Information:
MF is on scientific advisory boards for Teva Pharmaceutical Industries and Genmab A/S; has received funding for travel from Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries; is on editorial boards of the American Journal of Neuroradiology, BMC Musculoskeletal Disorders, Clinical Neurology and Neurosurgery, Erciyes Medical Journal, Journal of Neuroimaging, Journal of Neurovirology, The Lancet Neurology, Magnetic Resonance Imaging, Multiple Sclerosis, and Neurological Sciences; is as a consultant to Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries; serves on speakers' bureaus for Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries; and receives research support from Bayer Schering Pharma, Biogen-Dompè, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries, and Fondazione Italiana Sclerosi Multipla. MAR is as consultant to Bayer Schering Pharma; has received speakers' bureaus for Biogen-Dompé; and receives research support from the Italian Ministry of Health. FB serves on scientific advisory boards for Lundbeck, Bayer Schering Pharma, Sanofi- Aventis, UCB, Novartis, Biogen Idec, BioMS Medical, Merck Serono, and GE Healthcare; is on the editorial boards of Brain, Journal of Neurology, Neurosurgery and Psychiatry, European Radiology, Journal of Neurology, and Neuroradiology; has received speaker honoraria from Novartis, Merck Serono, and BioClinica; is a consultant for Sanofi-Aventis, UCB, Novartis, Biogen Idec, BioMS Medical, Medicinova, and GE Healthcare; and receives research support from the Dutch MS Research Foundation. WB receives research support from Teva Pharmaceutical Industries, BiogenIdec, Novartis, and Bayer Schering Pharma; is a member of scientific advisory boards of Teva Pharmaceutical Industries, Biogen Idec, and Sanofi-Aventis; serves on speakers' bureaus for Bayer Schering Pharma, BiogenIdec, Merck Serono, Teva Pharmaceutical Industries, Sanofi-Aventis, and Novartis; and is on editorial boards of Acta Neuropathologica, Journal of Neurology, and Therapeutic Advances in Neurological Disorder. JTC is as a consultant for NeuroRx Research. GC has received personal compensation for activities with Teva Neuroscience, Merck Serono, Bayer-Schering, Novartis, Sanofi-Aventis Pharmaceuticals, and Biogen-Dompè as a consultant, speaker, or scientific advisory board member. GCDL has received honoraria and travel expenses as an invited speaker for Bayer Schering and Teva Pharmaceutical Industries; and is supported by an AANF/CMSC John F Kurtzke Clinician-Scientist Award and a Goodger Scholarship (University of Oxford). NDS serves on scientific advisory boards for Merck Serono and Novartis; has received funding for travel from Merck Serono, Novartis, and Teva Pharmaceutical Industries; and has received speaker honoraria from Novartis, Teva Pharmaceutical Industries, Biogen-Dompè, Schering-Bayer, Sanofi-Aventis, and Merck Serono; he has no stocks, contract of employment, or named position on a company board. BJE receives funding from EU grant and NIH contract HHSN268200900060C. NE is on scientific advisory boards for Bayer Schering Pharma, Merck Serono, and Novartis; has received funding for travel from Bayer Schering Pharma, Biogen, Merck Serono, and Novartis; and has received research support from Biogen, Merck Serono, and Novartis. FF serves on scientific advisory boards for Bayer Schering, Biogen Idec, Merck Serono, Novartis, Teva Pharmaceutical Industries, and Sanofi-Aventis; is on the editorial boards of Cerebrovascular Diseases, Multiple Sclerosis, Polish Journal of Neurology and Neurosurgery, Stroke, Therapeutic Advances in Neurological Disorders, and Swiss Archives of Neurology and Psychiatry; and has received speaker honoraria from Biogen Idec, Merck Serono, Novartis, and Sanofi-Aventis. JJGG is on the editorial board of MS International and on the scientific advisory board of the Dutch MS Research Foundation; and has received speaker honoraria from Biogen Idec, MerckSerono BV, and Teva Pharmaceuticals. CL is listed as author and receives royalties for patent relating to Aquaporin-4 associated antibodies for diagnosis of neuromyelitis optica; receives royalties from the publication of Blue Books of Neurology: Multiple Sclerosis 3 (Saunders Elsevier, 2010); and receives research support from the National Institutes of Health, the National MS Society, and the Guthy Jackson Charitable Foundation. DHM has received research grants (held by University College London) from Biogen Idec, GlaxoSmithKline, Schering AG, and Novartis to do MRI analysis in multiple sclerosis trials; and has received honoraria and travel expenses for advisory committee work or as an invited speaker from Biogen Idec, GlaxoSmithKline, Bayer Schering, Novartis, and the US National Institutes of Health. DP has received research grant support from Biogen-Idec. BFGhP receives research support from the Saskatchewan Health Research Foundation. HL has received honoraria for lectures from Bayer Schering Pharma, Biogen Idec, Merck Serono, Teva Pharmaceutical Industries, and Novartis.
Funding Information:
Sponsors—This course was supported by an unrestricted education grant from Biogen.
PY - 2012/4
Y1 - 2012/4
N2 - The identification of pathological processes that could be targeted by therapeutic interventions is a major goal of research into multiple sclerosis (MS). Pathological assessment is the gold standard for such identification, but has intrinsic limitations owing to the limited availability of autopsy and biopsy tissue. MRI has gained a leading role in the assessment of MS because it allows doctors to obtain an ante mortem picture of the degree of CNS involvement. A number of correlative pathological and MRI studies have helped to define in vivo the pathological substrates of MS in focal lesions and normal-appearing white matter, not only in the brain, but also in the spinal cord. These studies have resulted in the identification of aspects of pathophysiology that were previously neglected, including grey matter involvement and vascular pathology. Despite these important achievements, numerous open questions still need to be addressed to resolve controversies about how the pathology of MS results in fixed neurological disability.
AB - The identification of pathological processes that could be targeted by therapeutic interventions is a major goal of research into multiple sclerosis (MS). Pathological assessment is the gold standard for such identification, but has intrinsic limitations owing to the limited availability of autopsy and biopsy tissue. MRI has gained a leading role in the assessment of MS because it allows doctors to obtain an ante mortem picture of the degree of CNS involvement. A number of correlative pathological and MRI studies have helped to define in vivo the pathological substrates of MS in focal lesions and normal-appearing white matter, not only in the brain, but also in the spinal cord. These studies have resulted in the identification of aspects of pathophysiology that were previously neglected, including grey matter involvement and vascular pathology. Despite these important achievements, numerous open questions still need to be addressed to resolve controversies about how the pathology of MS results in fixed neurological disability.
UR - http://www.scopus.com/inward/record.url?scp=84863344656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863344656&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(12)70003-0
DO - 10.1016/S1474-4422(12)70003-0
M3 - Review article
C2 - 22441196
AN - SCOPUS:84863344656
VL - 11
SP - 349
EP - 360
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 4
ER -